Cargando…
The development of an effective synthetic route of lesinurad (RDEA594)
BACKGROUND: Lesinurad is a novel selective uric acid salt transport protein 1 (URAT1) inhibitor which is approved in the USA for the treatment of gout. However, there are some shortcomings among the reported synthetic routes, such as expensive materials, environmental pollution and poor yield. RESUL...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583131/ https://www.ncbi.nlm.nih.gov/pubmed/29086884 http://dx.doi.org/10.1186/s13065-017-0316-y |